Opiant Pharmaceuticals Inc Watch

from 8-K 12 pages Voting Agreement

from 8-K 3 pages Termination Agreement

from 8-K 11 pages First Amendment to Note Purchase and Security Agreement

from 8-K 15 pages Amended and Restated License and Settlement Agreement Between Opiant Pharmaceuticals Inc. and Emergent Operations Ireland Limited

from 10-Q 7 pages Capacity Investment Agreement Between Aptar France Sas Aptargroup, Inc. and Opiant Pharmaceuticals, Inc. ***Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed***

from 8-K 17 pages Opiant Pharmaceuticals, Inc. 2021 Inducement Equity Incentive Plan

from 8-K 20 pages Opiant Pharmaceuticals, Inc. 2021 Inducement Equity Incentive Plan

from 8-K 4 pages Opiant Pharmaceuticals, Inc. Director Agreement

from 8-K 3 pages Material contract

from 8-K 43 pages Note Purchase and Security Agreement

from 8-K 6 pages Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update

from 8-K 19 pages Article 1.services

from 8-K 24 pages Master Services Agreement

from 10-K 8 pages Amendment No. 2 to License Agreement

from 8-K 48 pages Confidential Portions of This Document Have Been Redacted and Have Been Filed Separately With the Securities and Exchange Commission License Agreement Between Sanofi and Opiant Pharmaceuticals, Inc. Dated as of December 21, 2018

from 8-K/A 65 pages Confidentialtreatment Requested Confidential Portions of This Document Have Been Redacted and Have Been Filed Separately With the Securities and Exchange Commission

from 8-K 4 pages Opiant Pharmaceuticals, Inc. Director Agreement

from 8-K 58 pages Confidentialtreatment Requested Confidential Portions of This Document Have Been Redacted and Have Been Filed Separately With the Securities and Exchange Commission

from 8-K 12 pages Agreement for Reimbursement of Capital Expenditure and Service Fees Between Aesica Queenborough Limited and Opiant Pharmaceuticals Inc Relating to the Development, Manufacture and Supply of a Device Capable of Administering Nalmefene Hydrochloride

from 8-K 35 pages This Development Agreement (“Agreement”) Is Made on September 7, 2018 Between: (1) Aesica Queenborough Limited (Company Number 06350087) With Offices Located at Breakspear Park, Breakspear Way, Hemel Hempstead, Hertfordshire Hp2 4tz Uk (“Aesica”); and (2) Opiant Pharmaceuticals, Inc. With Offices Located at 201 Santa Monica Blvd., Suite 500, Santa Monica, California, 90401, USA (“Customer”). Introduction (A) Aesica Is a Developer and Manufacturer of Both Active Pharmaceutical Ingredients and Finished Dose Forms for the Pharmaceutical Industry. (B) Bespak (An Affiliate of Aesica) Is a Developer and Manufacturer of Medical Devices, Including the Unidose Xtra Device. (C) Customer Is Developing a Portfolio of Opioid Antagonist Nasal Sprays for Symptom-Driven Treatments of Substance Use and Eating Disorders. (D) Aesica Has Agreed to Undertake Development Work for Customer on the Terms Set Out in This Agreement With a View to Producing a Clinically Pre-Filled Unidose Xtra Device With Nalmefene Hydrochloride (“The Product”)